Want to see HK:1244 full AI Analyst Report?
3D Medicines, Inc. (1244) Ratios
3D Medicines, Inc. Ratios
HK:1244's free cash flow for Q2 2026 was $-56.34M. For the 2026 fiscal year, HK:1244's free cash flow was decreased by $-546.61K and operating cash flow was $-55.80M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.45 | 2.02 | 2.19 | 3.04 | 0.28 |
| Quick Ratio | 1.44 | 2.02 | 2.18 | 3.03 | 0.28 |
| Cash Ratio | 0.44 | 0.91 | 1.33 | 1.85 | 0.24 |
| Solvency Ratio | -0.41 | -0.34 | -0.89 | -2.30 | -0.43 |
| Operating Cash Flow Ratio | -0.39 | -0.43 | -0.29 | -0.74 | -0.12 |
| Short-Term Operating Cash Flow Coverage | -1.10 | -1.03 | -0.72 | -2.68 | -0.12 |
| Net Current Asset Value | $ 165.93M | $ 475.21M | $ 536.96M | $ 706.41M | $ -2.41B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.16 | 0.20 | 0.20 | 0.13 | 2.97 |
| Debt-to-Equity Ratio | 0.26 | 0.30 | 0.30 | 0.19 | -1.41 |
| Debt-to-Capital Ratio | 0.20 | 0.23 | 0.23 | 0.16 | 3.45 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.02 | 0.03 | 0.03 | 0.00 |
| Financial Leverage Ratio | 1.57 | 1.55 | 1.53 | 1.41 | -0.47 |
| Debt Service Coverage Ratio | -1.35 | -1.06 | -2.53 | -9.59 | -0.47 |
| Interest Coverage Ratio | -22.12 | -12.99 | -63.98 | -124.05 | -337.86 |
| Debt to Market Cap | 0.12 | 0.32 | 0.14 | 0.08 | 3.09 |
| Interest Debt Per Share | 0.64 | 1.01 | 1.27 | 3.93 | 80.77 |
| Net Debt to EBITDA | 0.09 | 0.91 | 0.73 | 0.51 | -1.64 |
| Profitability Margins | |||||
| Gross Profit Margin | 83.96% | 83.42% | 82.53% | 92.56% | 92.90% |
| EBIT Margin | -57.95% | -52.69% | -87.36% | -184.87% | -2423.33% |
| EBITDA Margin | -53.69% | -50.93% | -83.35% | -181.06% | -2402.43% |
| Operating Profit Margin | -31.64% | -27.70% | -78.31% | -68.06% | -856.71% |
| Pretax Profit Margin | -51.94% | -44.74% | -88.58% | -185.42% | -2425.86% |
| Net Profit Margin | -49.86% | -40.99% | -82.64% | -180.54% | -2379.84% |
| Continuous Operations Profit Margin | -51.92% | -44.74% | -88.59% | -185.42% | -2425.86% |
| Net Income Per EBT | 95.99% | 91.62% | 93.29% | 97.37% | 98.10% |
| EBT Per EBIT | 164.17% | 161.53% | 113.12% | 272.43% | 283.16% |
| Return on Assets (ROA) | -18.95% | -15.02% | -36.72% | -76.90% | -135.25% |
| Return on Equity (ROE) | -29.74% | -23.27% | -56.01% | -108.63% | 64.08% |
| Return on Capital Employed (ROCE) | -20.42% | -16.94% | -53.55% | -40.40% | 23.60% |
| Return on Invested Capital (ROIC) | -16.14% | -13.11% | -43.12% | -36.05% | -56.18% |
| Return on Tangible Assets | -18.96% | -15.03% | -36.74% | -76.95% | -135.37% |
| Earnings Yield | -15.11% | -26.29% | -32.58% | -60.01% | -143.38% |
| Efficiency Ratios | |||||
| Receivables Turnover | 16.08 | 9.31 | 116.31 | 7.27 | 0.93 |
| Payables Turnover | 0.64 | 1.45 | 1.54 | 2.66 | 1.14 |
| Inventory Turnover | 16.28 | 18.21 | 24.05 | 35.30 | 329.00 |
| Fixed Asset Turnover | 2.59 | 3.02 | 3.29 | 3.16 | 0.50 |
| Asset Turnover | 0.38 | 0.37 | 0.44 | 0.43 | 0.06 |
| Working Capital Turnover Ratio | 1.06 | 0.81 | 0.93 | -0.73 | -0.06 |
| Cash Conversion Cycle | -525.01 | -193.26 | -218.25 | -76.76 | 75.50 |
| Days of Sales Outstanding | 22.70 | 39.20 | 3.14 | 50.20 | 393.73 |
| Days of Inventory Outstanding | 22.42 | 20.05 | 15.17 | 10.34 | 1.11 |
| Days of Payables Outstanding | 570.12 | 252.51 | 236.56 | 137.30 | 319.34 |
| Operating Cycle | 45.12 | 59.25 | 18.31 | 60.54 | 394.84 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.61 | -0.86 | -0.63 | -6.13 | -9.66 |
| Free Cash Flow Per Share | -0.61 | -1.02 | -0.66 | -7.32 | -11.10 |
| Dividend Paid and CapEx Coverage Ratio | -6409.08 | -4.56 | -22.84 | -5.16 | -6.69 |
| Capital Expenditure Coverage Ratio | -6409.08 | -4.56 | -22.84 | -5.16 | -6.69 |
| Operating Cash Flow Coverage Ratio | -0.98 | -0.89 | -0.51 | -1.59 | -0.12 |
| Operating Cash Flow to Sales Ratio | -0.42 | -0.47 | -0.23 | -0.49 | -6.26 |
| Free Cash Flow Yield | -12.75% | -35.92% | -9.36% | -19.49% | -43.34% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.65 | -3.80 | -3.07 | -1.67 | -0.70 |
| Price-to-Sales (P/S) Ratio | 3.30 | 1.56 | 2.54 | 3.01 | 16.60 |
| Price-to-Book (P/B) Ratio | 1.97 | 0.89 | 1.72 | 1.81 | -0.45 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.84 | -2.78 | -10.68 | -5.13 | -2.31 |
| Price-to-Operating Cash Flow Ratio | -7.84 | -3.30 | -11.15 | -6.12 | -2.65 |
| Price-to-Earnings Growth (PEG) Ratio | 1.66 | 0.06 | 0.03 | 0.04 | -0.00 |
| Enterprise Value Multiple | -6.06 | -2.15 | -2.32 | -1.15 | -2.33 |
| Enterprise Value | 1.16B | 488.10M | 1.23B | 1.19B | 3.38B |
| EV to EBITDA | -6.06 | -2.15 | -2.32 | -1.15 | -2.33 |
| EV to Sales | 3.25 | 1.10 | 1.93 | 2.09 | 56.07 |
| EV to Free Cash Flow | -7.73 | -1.96 | -8.14 | -3.56 | -7.79 |
| EV to Operating Cash Flow | -7.73 | -2.32 | -8.49 | -4.25 | -8.96 |
| Tangible Book Value Per Share | 2.22 | 2.87 | 3.81 | 19.67 | -58.22 |
| Shareholders’ Equity Per Share | 2.43 | 3.20 | 4.10 | 20.73 | -57.31 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.45 | 1.82 | 2.78 | 12.47 | 1.54 |
| Net Income Per Share | -0.72 | -0.75 | -2.30 | -22.52 | -36.72 |
| Tax Burden | 0.96 | 0.92 | 0.93 | 0.97 | 0.98 |
| Interest Burden | 0.90 | 0.85 | 1.01 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.44 | 0.41 | 0.67 | 0.62 | 6.16 |
| SG&A to Revenue | 0.72 | 0.71 | 0.34 | 0.25 | 2.51 |
| Stock-Based Compensation to Revenue | 0.07 | 0.07 | 0.47 | 0.25 | 2.73 |
| Income Quality | 0.84 | 1.06 | 0.26 | 0.39 | 0.26 |
Currency in CNY